中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(7): 1464-1468

Research advances in non-cirrhotic intrahepatic presinusoidal portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.003
  • 1.

    Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

  • 2.

    National Clinical Research Center for Digestive Diseases, Beijing 100050, China

More Information
  • Corresponding author: YOU Hong, youhongliver@ccmu.edu.cn(ORCID: 0000-0001-9409-1158)
  • Received Date: 2022-05-04
  • Accepted Date: 2022-06-05
  • Published Date: 2022-07-20
    Abstract
  • Non-cirrhotic intrahepatic presinusoidal portal hypertension is a subtype of non-cirrhotic portal hypertension, and patients with this disease have the symptoms of portal hypertension and do not have the pathological evidence for liver cirrhosis, with normal or slightly abnormal hepatic venous pressure gradient. This disease is easily missed or misdiagnosed due to its complex etiology; therefore, radiological examination and histological examination should be combined in clinical practice to make a confirmed diagnosis, and related therapies should be initiated at the right time to reduce portal venous pressure. Further studies are needed to verify the efficacy of prophylactic anticoagulant therapy.

     

    • FullText(HTML)
  • loading
    • References(33)
  • [1]
    HE FL, MA L, LI YR, et al. Non-cirrhotic portal hypertension: the highlight of its diagnosis[J]. J Prac Hepatol, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001.

    何福亮, 马琳, 李悦榕, 等. 非肝硬化门静脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001.
    [2]
    KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376.
    [3]
    ZHOU H, FENG XN, REN H, et al. Clinical features and hepatic venous pressure gradientchanges in patients with noncirrhotic portal hypertension[J]. J Prac Hepatol, 2021, 24(3): 415-418. DOI: 10.3969/j.issn.1672-5069.2021.03.028.

    周慧, 冯晓宁, 任浩, 等. 非肝硬化门脉高压患者临床特点分析[J]. 实用肝脏病杂志, 2021, 24(3): 415-418. DOI: 10.3969/j.issn.1672-5069.2021.03.028.
    [4]
    KHANNA R, SARIN SK. Noncirrhotic portal hypertension: current and emerging perspectives[J]. Clin Liver Dis, 2019, 23(4): 781-807. DOI: 10.1016/j.cld.2019.07.006.
    [5]
    SCHOUTEN JN, VERHEIJ J, SEIJO S. Idiopathic non-cirrhotic portal hypertension: a review[J]. Orphanet J Rare Dis, 2015, 10: 67. DOI: 10.1186/s13023-015-0288-8.
    [6]
    NORTHUP PG, GARCIA-PAGAN JC, GARCIA-TSAO G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 73(1): 366-413. DOI: 10.1002/hep.31646.
    [7]
    ISABEL FIEL M, THUNG SN, HYTIROGLOU P, et al. Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis[J]. Am J Surg Pathol, 2007, 31(4): 607-614. DOI: 10.1097/01.pas.0000213425.76621.f1.
    [8]
    SCHOUTEN JN, NEVENS F, HANSEN B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study[J]. Aliment Pharmacol Ther, 2012, 35(12): 1424-1433. DOI: 10.1111/j.1365-2036.2012.05112.x.
    [9]
    BISSONNETTE J, RAUTOU PE, VALLA DC. Idiopathic non-cirrhotic portal hypertension: An update[J]. Presse Med, 2015, 44(10): 1009-1015. DOI: 10.1016/j.lpm.2015.06.007.
    [10]
    de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
    [11]
    SIRAMOLPIWAT S, SEIJO S, MIQUEL R, et al. Idiopathic portal hypertension: natural history and long-term outcome[J]. Hepatology, 2014, 59(6): 2276-2285. DOI: 10.1002/hep.26904.
    [12]
    GUIDO M, SARCOGNATO S, SONZOGNI A, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition[J]. Liver Int, 2016, 36(3): 454-460. DOI: 10.1111/liv.12936.
    [13]
    GUIDO M, SARCOGNATO S, SACCHI D, et al. Pathology of idiopathic non-cirrhotic portal hypertension[J]. Virchows Arch, 2018, 473(1): 23-31. DOI: 10.1007/s00428-018-2355-8.
    [14]
    RAJESH S, MUKUND A, SUREKA B, et al. Non-cirrhotic portal hypertension: an imaging review[J]. Abdom Radiol (NY), 2018, 43(8): 1991-2010. DOI: 10.1007/s00261-018-1570-8.
    [15]
    GUERRA MR, NAINI BV, SCAPA JV, et al. Obliterative portal venopathy: A histopathologic finding associated with chronic antibody-mediated rejection in pediatric liver allografts[J]. Pediatr Transplant, 2018, 22(2): 13124. DOI: 10.1111/petr.13124.
    [16]
    ETZION O, TAKYAR V, NOVACK V, et al. Spleen and liver volumetrics as surrogate markers of hepatic venous pressure gradient in patients with noncirrhotic portal hypertension[J]. Hepatol Commun, 2018, 2(8): 919-928. DOI: 10.1002/hep4.1198.
    [17]
    LEE H, REHMAN AU, FIEL MI. Idiopathic noncirrhotic portal hypertension: an appraisal[J]. J Pathol Transl Med, 2016, 50(1): 17-25. DOI: 10.4132/jptm.2015.09.23.
    [18]
    SCHOUTEN JN, NEVENS F, HANSEN B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study[J]. Aliment Pharmacol Ther, 2012, 35(12): 1424-1433. DOI: 10.1111/j.1365-2036.2012.05112.x.
    [19]
    de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
    [20]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
    [21]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Corrigendum to 'Baveno Ⅶ - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974][J]. J Hepatol, 2022. DOI: 10.1016/j.jhep.2022.03.024. [Online ahead of print]
    [22]
    WORRAN K, SEMMLER G, JACHS M, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(2): e251-e266. DOI: 10.1016/j.cgh.2020.11.039.
    [23]
    O'BRIEN K, FONT-MONTGOMERY E, LUKOSE L, et al. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease[J]. J Pediatr Gastroenterol Nutr, 2012, 54(1): 83-89. DOI: 10.1097/MPG.0b013e318228330c.
    [24]
    LASAGNI A, CADAMURO M, MORANA G, et al. Fibrocystic liver disease: novel concepts and translational perspectives[J]. Transl Gastroenterol Hepatol, 2021, 6: 26. DOI: 10.21037/tgh-2020-04.
    [25]
    SRINATH A, SHNEIDER BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease[J]. J Pediatr Gastroenterol Nutr, 2012, 54(5): 580-587. DOI: 10.1097/MPG.0b013e31824711b7.
    [26]
    ALSOMALI MI, YEARSLEY MM, LEVIN DM, et al. Diagnosis of congenital hepatic fibrosis in adulthood[J]. Am J Clin Pathol, 2020, 153(1): 119-125. DOI: 10.1093/ajcp/aqz140.
    [27]
    ZHAO XY, ZHANG X, WANG TL, et al. Clinical and pathological features of patients with congenital hepatic fibrosis[J]. J Clin Hepatol, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025.

    赵新颜, 张新, 王泰龄, 等. 先天性肝纤维化14例临床病理特点[J]. 临床肝胆病杂志, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025.
    [28]
    AKHAN O, KARAOSMANOǦLU AD, ERGEN B. Imaging findings in congenital hepatic fibrosis[J]. Eur J Radiol, 2007, 61(1): 18-24. DOI: 10.1016/j.ejrad.2006.11.007.
    [29]
    MAMONE G, CAROLLO V, CORTIS K, et al. Magnetic resonance imaging of fibropolycystic liver disease: the spectrum of ductal plate malformations[J]. Abdom Radiol (NY), 2019, 44(6): 2156-2171. DOI: 10.1007/s00261-019-01966-9.
    [30]
    WEHRMAN A, KRIEGERMEIER A, WEN J. Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease[J]. Front Pediatr, 2017, 5: 124. DOI: 10.3389/fped.2017.00124.
    [31]
    GARCIA-TSAO G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT)[J]. J Hepatol, 2007, 46(3): 499-507. DOI: 10.1016/j.jhep.2006.12.008.
    [32]
    IYER VN, SABERI B, HEIMBACH JK, et al. Liver transplantation trends and outcomes for hereditary hemorrhagic telangiectasia in the United States[J]. Transplantation, 2019, 103(7): 1418-1424. DOI: 10.1097/TP.0000000000002491.
    [33]
    DUMORTIER J, DUPUIS-GIROD S, VALETTE PJ, et al. Recurrence of hereditary hemorrhagic telangiectasia after liver transplantation: clinical implications and physiopathological insights[J]. Hepatology, 2019, 69(5): 2232-2240. DOI: 10.1002/hep.30424.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (531) PDF downloads(147) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return